Spiriva and CHRONIC OBSTRUCTIVE PULMONARY DISEASE

5,790 reports of this reaction

2.2% of all Spiriva reports

#9 most reported adverse reaction

Overview

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is the #9 most commonly reported adverse reaction for Spiriva, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 5,790 FDA adverse event reports linking Spiriva to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This represents approximately 2.2% of all 266,551 adverse event reports for this drug.

Patients taking Spiriva who experience chronic obstructive pulmonary disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CHRONIC OBSTRUCTIVE PULMONARY DISEASE5,790 of 266,551 reports

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is a less commonly reported adverse event for Spiriva, but still significant enough to appear in the safety profile.

Other Side Effects of Spiriva

In addition to chronic obstructive pulmonary disease, the following adverse reactions have been reported for Spiriva:

INCORRECT ROUTE OF DRUG ADMINISTRATION — 23,308 reports
DYSPNOEA — 20,984 reports
ASTHMA — 9,662 reports
DRUG INEFFECTIVE — 9,031 reports
COUGH — 8,053 reports
PNEUMONIA — 7,976 reports
WHEEZING — 6,001 reports
PRODUCT QUALITY ISSUE — 5,895 reports
FATIGUE — 5,060 reports
OFF LABEL USE — 4,482 reports

Other Drugs Associated with CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The following drugs have also been linked to chronic obstructive pulmonary disease in FDA adverse event reports:

ACETYLCYSTEINE ACLIDINIUM BROMIDE Advair ALBUTEROL ARFORMOTEROL TARTRATE BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE FLUTICASONE PROPIONATE AND SALMETEROL FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE GLYCOPYRROLATE IPRATROPIUM BROMIDE IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE MANGANESE SULFATE ROFLUMILAST SALMETEROL XINAFOATE Symbicort THEOPHYLLINE THEOPHYLLINE ANHYDROUS TIOTROPIUM BROMIDE

Frequently Asked Questions

Does Spiriva cause CHRONIC OBSTRUCTIVE PULMONARY DISEASE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE has been reported as an adverse event in 5,790 FDA reports for Spiriva. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CHRONIC OBSTRUCTIVE PULMONARY DISEASE with Spiriva?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE accounts for approximately 2.2% of all adverse event reports for Spiriva, making it a notable side effect.

What should I do if I experience CHRONIC OBSTRUCTIVE PULMONARY DISEASE while taking Spiriva?

If you experience chronic obstructive pulmonary disease while taking Spiriva, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Spiriva Full Profile All Drugs Causing CHRONIC OBSTRUCTIVE PULMONARY DISEASE Boehringer Ingelheim Pharmaceuticals, Inc. Drugs

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.